Neurocrine Biosciences (NASDAQ:NBIX) Director Sells $1,197,864.00 in Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director George Morrow sold 7,200 shares of Neurocrine Biosciences stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of $166.37, for a total value of $1,197,864.00. Following the completion of the transaction, the director owned 10,386 shares in the company, valued at approximately $1,727,918.82. The trade was a 40.94% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Neurocrine Biosciences Stock Down 3.8%

Shares of NBIX stock opened at $159.76 on Friday. Neurocrine Biosciences, Inc. has a twelve month low of $122.14 and a twelve month high of $186.12. The company has a market cap of $16.17 billion, a P/E ratio of 23.70, a P/E/G ratio of 0.74 and a beta of 0.36. The business has a fifty day simple moving average of $147.04 and a 200 day simple moving average of $147.90.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Monday, November 2nd. The company reported $3.29 earnings per share for the quarter, beating the consensus estimate of $1.91 by $1.38. The business had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.04 billion. Neurocrine Biosciences had a return on equity of 23.39% and a net margin of 18.98%. Neurocrine Biosciences’s revenue was up 41.3% compared to the same quarter last year. During the same period last year, the firm posted $2.04 earnings per share. As a group, equities research analysts anticipate that Neurocrine Biosciences, Inc. will post 7.66 earnings per share for the current fiscal year.

Institutional Trading of Neurocrine Biosciences

A number of hedge funds have recently made changes to their positions in NBIX. Fifth Third Bancorp raised its holdings in Neurocrine Biosciences by 6.6% during the 3rd quarter. Fifth Third Bancorp now owns 32,218 shares of the company’s stock worth $4,570,000 after purchasing an additional 2,001 shares during the last quarter. New Mexico Educational Retirement Board boosted its stake in shares of Neurocrine Biosciences by 6.6% in the 3rd quarter. New Mexico Educational Retirement Board now owns 21,000 shares of the company’s stock valued at $2,979,000 after purchasing an additional 1,300 shares during the last quarter. Maryland State Retirement & Pension System boosted its stake in shares of Neurocrine Biosciences by 2.2% in the 3rd quarter. Maryland State Retirement & Pension System now owns 5,714 shares of the company’s stock valued at $810,000 after purchasing an additional 123 shares during the last quarter. Jacobi Capital Management LLC acquired a new stake in shares of Neurocrine Biosciences during the third quarter worth $42,000. Finally, Philadelphia Trust Co. increased its position in shares of Neurocrine Biosciences by 0.4% during the third quarter. Philadelphia Trust Co. now owns 30,270 shares of the company’s stock worth $4,293,000 after buying an additional 135 shares during the period. 92.59% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

NBIX has been the topic of several research reports. Truist Financial lifted their price target on shares of Neurocrine Biosciences from $200.00 to $213.00 and gave the company a “buy” rating in a report on Monday, August 3rd. Guggenheim increased their price objective on shares of Neurocrine Biosciences from $207.00 to $224.00 and gave the company a “buy” rating in a research note on Wednesday. Wall Street Zen downgraded shares of Neurocrine Biosciences from a “buy” rating to a “hold” rating in a research note on Sunday, August 9th. Zacks Research lowered shares of Neurocrine Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 4th. Finally, Piper Sandler boosted their target price on shares of Neurocrine Biosciences from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $202.32.

More Neurocrine Biosciences News

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Neurocrine reported third-quarter revenue of $1.12 billion, up 41% year over year and above estimates, with EPS of $3.29 versus a $1.91 consensus. The company also raised its 2026 INGREZZA net-sales outlook to $2.9–$2.925 billion, reinforcing the growth case for its leading product. Q3 results and outlook
• Positive Sentiment: New survey findings showed fewer work or school disruptions among adults with tardive dyskinesia after starting INGREZZA: the share reporting disruptions fell from 57% to 21%, and average missed days declined from 5.6 to 2.0 per month. The results may bolster confidence in the treatment’s patient benefits. INGREZZA survey findings
• Positive Sentiment: Analysts raised price targets following the earnings report, including Morgan Stanley, Canaccord Genuity, RBC and Piper Sandler. Guggenheim also lifted its target to $224 and maintained a Buy rating, adding to the supportive analyst backdrop. Guggenheim rating
• Neutral Sentiment: After a sharp post-earnings advance, some investors may be taking profits, which could weigh on the shares despite the strong operating update. A director’s sale of 300 shares was made under a pre-arranged trading plan and appears small relative to his remaining holdings.
• Negative Sentiment: A report flagged potential integration challenges and legacy liabilities related to Neurocrine’s Soleno acquisition, risks that could complicate the expected value from the deal. Soleno acquisition risks

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is a San Diego-based biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and psychiatric disorders. The company’s research programs target conditions in which treatments may address significant unmet medical needs.

Neurocrine’s leading product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved in the United States for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease.